Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)
Stopped early · Phase 1
Conditions studied: Amyotrophic Lateral Sclerosis
In brief
The primary objective is to evaluate the long-term safety and tolerability of BIIB078 in participants with chromosome 9 open reading frame 72-amyotrophic lateral sclerosis (C9ORF72-ALS). The secondary objective is to evaluate the pharmacokinectic (PK) of BIIB078 in participants with C9ORF72-ALS.
Key facts
- Study ID
- NCT04288856
- Run by
- Biogen
- People needed
- 75
- Starts
- 2020-04-28
- Expected to finish
- 2022-05-03
- Last updated by the study team
- 2023-04-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — La Jolla, California, United States
- Research Site — Los Angeles, California, United States
- Research Site — Palo Alto, California, United States
- Research Site — Jacksonville, Florida, United States
- Research Site — Miami, Florida, United States
- Research Site — Atlanta, Georgia, United States
- Research Site — Baltimore, Maryland, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — St Louis, Missouri, United States
- Research Site — Lincoln, Nebraska, United States
- Research Site — New York, New York, United States
- Research Site — Knoxville, Tennessee, United States
- Research Site — Calgary, Alberta, Canada
- Research Site — Edmonton, Alberta, Canada
- Research Site — Toronto, Ontario, Canada
- Research Site — Montreal, Quebec, Canada
- Research Site — Utrecht, Netherlands
- Research Site — Sankt Gallen, Switzerland
- Research Site — London, Greater London, United Kingdom
- Research Site — London, Greater London, United Kingdom
- Research Site — Sheffield, South Yorkshire, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.